Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where consensus estimates seem disconnected from reality.

Two Stocks to Sell:

Flowers Foods (FLO)

Consensus Price Target: $7.90 (27.5% implied return)

With Wonder Bread as its premier brand, Flowers Foods (NYSE: FLO) is a packaged foods company that focuses on bakery products such as breads, buns, and cakes.

Why Do We Avoid FLO?

1. Declining unit sales over the past two years imply it may need to invest in product improvements to get back on track
2. Forecasted revenue decline of 3.1% for the upcoming 12 months implies demand will fall off a cliff
3. Earnings per share fell by 24.3% annually over the last three years while its revenue grew, showing its incremental sales were much less profitable

At $6.20 per share, Flowers Foods trades at 9.1x forward P/E. Check out our free in-depth research report to learn more about why FLO doesn’t pass our bar.

Huntington Ingalls (HII)

Consensus Price Target: $368.42 (31% implied return)

Building Nimitz-class aircraft carriers used in active service, Huntington Ingalls (NYSE: HII) develops marine vessels and their mission systems and maintenance services.

Why Do We Think HII Will Underperform?

1. Annual sales growth of 5.8% over the last two years lagged behind its industrials peers as its large revenue base made it difficult to generate incremental demand
2. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 1.9% annually
3. Free cash flow margin dropped by 5.7 percentage points over the last five years, implying the company became more capital intensive as competition picked up

Huntington Ingalls’s stock price of $281.25 implies a valuation ratio of 14.9x forward P/E. Dive into our free research report to see why there are better opportunities than HII.

One Stock to Watch:

Boston Scientific (BSX)

Consensus Price Target: $62.41 (38.2% implied return)

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Why Are We Fans of BSX?

1. Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 15.8% over the past two years
2. Additional sales over the last five years increased its profitability as the 18.6% annual growth in its earnings per share outpaced its revenue
3. Free cash flow margin jumped by 12.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends

Boston Scientific is trading at $45.17 per share, or 13.7x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.

Stocks We Like Even More

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.